Saluggia, Italy. - CID is pleased to announce that its latest Drug Eluting Stent (DES), Cre8™, has extended the available size matrix receiving the CE mark for the length 31mm – in small sizes - and the lengths 38 mm for the entire product range.

Since the first CE mark of CRE8™ obtained in 2011, the CID portfolio is expanding quickly and now the polymer-free DES is available in diameter from 2.5 mm to 4.5 mm and lengths from 8 mm to 38 mm.

The NEXT randomized study has shown that Cre8™ is superior to TAXUS™ Liberté® improving DES performance specifically in complex patients such as diabetics who usually present long coronary lesions. With the today CE mark a wider spectrum of lesions can benefit from the Cre8™ unique features.

The Cre8™ polymer-free DES embodies the most advanced DES technologies to treat coronary vascular disease. Its unique distinctive features - Abluminal Reservoir Technology, Amphilimus™ Formulation and Bio Inducer Surface - make Cre8™ the only very effective Polymer-Free DES today available.

The proprietary Abluminal Reservoir Technology provides a consistent drug loading onto the stent platform, thus enabling a controlled and directed elution exclusively targeted to the vessel wall. The innovative Amphilimus™ formulation, that is Sirolimus plus an organic acid, is the first known use of a carrier to enhance drug bioavailability and drug distribution to the entire vessel wall. The Bio Inducer Surface, a second generation integral pure carbon coating, demonstrates excellent results in terms of stent endothelialization and struts coverage.

Source: CID SpA